Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B
Open Access
- 20 May 2026
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113178
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Dane G. Hansen Foundation
- National Institutes of Health (R01CA53840)
- National Institutes of Health (CA45508)
- Cold Spring Harbor Laboratory
- Coins for Alzheimer's Research Trust
This publication has 70 references indexed in Scilit:
- Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency DisorderPediatric Drugs, 2025
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trialEuropean Journal of Paediatric Neurology, 2024
- Overexpression of forebrain PTP1B leads to synaptic and cognitive impairments in obesityBrain, Behavior, and Immunity, 2024
- Protein Tyrosine Phosphatases: Mighty oaks from little acorns growIUBMB Life, 2023
- Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disordersBiomedicine & Pharmacotherapy, 2022
- Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency DisorderNeurotherapeutics, 2022
- Increased DNA Damage and Apoptosis in CDKL5-Deficient NeuronsMolecular Neurobiology, 2020
- Inhibitory effects of glucagon-like peptide-1 receptor on epilepsyBiochemical and Biophysical Research Communications, 2019
- CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary FunctionCell Reports, 2018
- Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1Biological Psychiatry, 2016